<DOC>
	<DOCNO>NCT02168803</DOCNO>
	<brief_summary>The main purpose study measure much drug get blood stream long take body get rid give day 12 , 24 , 52 week participant abnormal amount cholesterol and/or fat blood stream . Information side effect may occur also collect . This study also evaluate study drug reacts body give day 12 , 24 52 week body respond return normal treatment complete . The relationship study drug result study drug reacts body may explore , need .</brief_summary>
	<brief_title>A Study Evacetrapib Participants With Abnormal Cholesterol</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Generally healthy participant stable medical condition , investigator 's opinion , significantly alter disposition drug , place participant increase risk participate study , interfere interpretation data meet one follow criterion : Elevated lowdensity lipoprotein cholesterol ( LDLC ) great 100 milligram per deciliter ( mg/dL ) , OR Low highdensity lipoprotein cholesterol ( HDLC ) less 45 mg/dL ( men ) ; le 50 mg/dL ( woman ) , OR Hypercholesterolemia stable statin therapy least 3 month Have body mass index ( BMI ) 18 37 kilogram per square meter ( kg/m^2 ) , inclusive , screen Have know allergy intolerance evacetrapib , relate compound Have history recurrent rashes chronic skin condition Have significant history current chronic , active inflammatory condition Have history current evidence significant neurological disorder Have longstanding diabetes insulin require Have history current symptom malabsorption syndrome , history gastric bypass surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>abnormal cholesterol</keyword>
</DOC>